Elizabeth Clara Barroso, Jorge Luís Nobre Rodrigues, Valéria Góes Ferreira Pinheiro, Creuza L. Campelo
Multidrug-resistant tuberculosis (MDR-TB) is a worldwide concern but its magnitude in the state of Ceará - Northeastern Brazil has been so far unknown. Objectives: To determine the prevalence of MDR-TB among us as well as the sesceptibility of Mycobacterium tuberculosis to antituberculosis drugs. Methods: A retrospective study was conducted using 1,500 susceptibility tests (ST) for rifampin (RFM), isoniazid (INH), streptomycin (SM), pyrazinamide (PYZ), ethambutol (ETM) and ethionamide (ETH) that were performed at the Central Laboratory of the State of Ceará (LACEN) between 1990 and 1999. The proportion method test was used. Results: Of the 1,500 stains studied, 404 (27%) were resistant to at least one drug, including both primary and acquired resistance. MDR-TB, defined as resistance to at least rifampin and isoniazid was observed in 266 (17.7%) patients. During the study period, there were 41,073 TB cases and MDR-TB prevalence was 0.65% in our state. Among the patients studied, 62.3% were men and mean age was 40.17 ± 14.62. Overall prevalence for single-drug resistance was 8.1% (INH = 5.7%; SM = 1.5%; and RFP = 0.9%). Resistance to 2, 3, 4, 5 and 6 drugs was, respectively, 10.8%; 3.1%; 0.9%; 1.5%; and 2.9%. HIV testing was performed in all inpatients and some outpatients (total of 86 patients) and revealed that they were all HIV negative. The probability of 5-year survival (138 patients assessed) was greater in the MDR-TB group treated with alternative drugs, including the patients of the failure group. Conclusion: The MDR-TB prevalence rate found in this study is intermediate in comparison with those reported in Brazil and the other parts of the world. Preventive approaches, early diagnosis and the development of effective, safe and relatively inexpensive new drugs should be stimulated.
Keywords: Multidrug-resistant tuberculosis. Prevalence. Survival probability.